BIOTECanada Announces Addition of Directors to Board of Directors

article content

TORONTO — Following BIOTECanada’s Annual General Meeting, the Board of Directors announces the election of three additional Directors to the Board. The new directors include:

  • colleen coxsonCountry Manager, Alnylam Pharmaceuticals
  • round pachecoPresident and General Manager, Eli Lilly Canada
  • nancypei, Partner, Smart and Biggar

“On behalf of the BIOTECanada team and member companies, I thank outgoing Directors John Norman (Partner Gowling WLG Canada LLP) and Shermaine Tilley, Managing Partner (CTI Life Sciences Fund) for their time and commitment to the Association,” he commented. Andrew Casey, President and CEO of BIOTECanada. “Canada’s biotech ecosystem is built on a reputation for strong scientific research and includes a diverse mix of early-stage companies, universities, incubators/accelerators, think tanks, investors and multinational pharmaceutical/biotech companies. I look forward to working with the Board as we continue our quest to grow Canada’s life sciences sector and biomanufacturing capacity, including attracting investment and talent to the sector.”

article content

The Board of Directors of BIOTECCanada 2022-2023

  • Gordon C McCauleyPresident and CEO AdMare BioInnovations (Chairman)
  • Robert Bellini, President and CEO, Bellus Health (Vice President)
  • Oliver Technow, CEO, BioVectra Inc. (Treasurer)
  • Andres Casey, President and CEO, BIOTECanada (Secretary)
  • norma biln, CEO, Augurex
  • NealCarter, President and Founder, Okanagan Specialty Fruits
  • andres Haigh, President and CEO, Adaptyn Bioscience
  • Alok Kanti, General Manager, Bayer Canada
  • Melissa Koomey, Vice President and General Manager, Gilead Sciences Canada
  • AJ (Sandy) Marshall, President, Bioindustrial Innovation Canada
  • Paul Petrelli, President and CEO, Jazz Pharmaceuticals
  • Tracey Ramsey, Vice President and General Manager, AbbVie Canada
  • sanj Singh, President and CEO, Temple Therapeutics B.V.
  • jamie Stiff, CEO, Genesys Capital
  • Ali Teherani, Partner, Amplitude Ventures

View the source version on


[email protected]


Leave a Comment